A daily pill of Eli Lilly helped patients with type 2 diabetes to improve their blood sugar and lose weight, announced on Thursday advanced results that could propel new generation treatment on the market.
The drug, Orforglipron, has produced results almost comparable to the advantages of available GLP-1 drugs, which are mainly weekly injectable treatments. Companies have run to develop more practical and powerful obesity treatments, including pills. The idea is that drugs that are easier to take to give companies an advantage in the competitive market and expand their patient bases.
Lilly’s actions jumped in trade before the market on Thursday.
This article is exclusive to stat + subscribers
Unlock this article – plus daily coverage and analysis of the pharmaceutical industry – as a STAT +subscription.
Do you already have an account? Connect
Show all plans
